Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib. - Info and Reading Options
By Harvey, R Donald
"Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib." and the language of the book is English.
“Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” Metadata:
- Title: ➤ Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.
- Author: Harvey, R Donald
- Language: English
Edition Identifiers:
- Internet Archive ID: pubmed-PMC4020895
AI-generated Review of “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.”:
"Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib." Description:
The Internet Archive:
This article is from <a href="//archive.org/search.php?query=journaltitle%3A%28Clinical%20Pharmacology%20:%20Advances%20and%20Applications%29" rel="nofollow">Clinical Pharmacology : Advances and Applications</a>, <a href="//archive.org/search.php?query=journaltitle%3A%28Clinical%20Pharmacology%20:%20Advances%20and%20Applications%29%20AND%20volume%3A%286%29" rel="nofollow">volume 6</a>.<h2>Abstract</h2>Carfilzomib, a selective proteasome inhibitor approved in the USA in 2012, is a single agent for relapsed and refractory multiple myeloma. Carfilzomib is administered as a 2–10-minute infusion on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle at a starting dose of 20 mg/m2 for cycle 1 and a target dose of 27 mg/m2 thereafter. In the pivotal Phase II study (PX-171-003-A1), carfilzomib 20/27 mg/m2 provided durable responses in a heavily pretreated population with relapsed and refractory multiple myeloma (n=266), with an overall response rate of 22.9% and a median duration of response of 7.8 months. In an integrated safety analysis of four Phase II studies, common adverse events (32.7%–55.5%) included fatigue, anemia, nausea, thrombocytopenia, dyspnea, and diarrhea. Grade 3/4 adverse events were generally hematologic and included thrombocytopenia (23.4%), anemia (22.4%), and lymphopenia (18.1%). Serious adverse events included pneumonia (9.9%), acute renal failure (4.2%), pyrexia (3.4%), and congestive heart failure (3.4%). New or worsening peripheral neuropathy was infrequent (13.9% overall, 1.3% grade 3, no grade 4). This review discusses findings of the integrated safety analysis and provides practical experience from a single institution in managing treatment-related and disease-related adverse events. Individualized treatment with proactive management of side effects and complications allows patients with advanced multiple myeloma to remain on carfilzomib for extended periods.
Read “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.”:
Read “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” by choosing from the options below.
Available Downloads for “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.”:
"Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib." is available for download from The Internet Archive in "texts" format, the size of the file-s is: 8.19 Mbs, and the file-s went public at Wed Oct 22 2014.
Legal and Safety Notes
Copyright Disclaimer and Liability Limitation:
A. Automated Content Display
The creation of this page is fully automated. All data, including text, images, and links, is displayed exactly as received from its original source, without any modification, alteration, or verification. We do not claim ownership of, nor assume any responsibility for, the accuracy or legality of this content.
B. Liability Disclaimer for External Content
The files provided below are solely the responsibility of their respective originators. We disclaim any and all liability, whether direct or indirect, for the content, accuracy, legality, or any other aspect of these files. By using this website, you acknowledge that we have no control over, nor endorse, the content hosted by external sources.
C. Inquiries and Disputes
For any inquiries, concerns, or issues related to the content displayed, including potential copyright claims, please contact the original source or provider of the files directly. We are not responsible for resolving any content-related disputes or claims of intellectual property infringement.
D. No Copyright Ownership
We do not claim ownership of any intellectual property contained in the files or data displayed on this website. All copyrights, trademarks, and other intellectual property rights remain the sole property of their respective owners. If you believe that content displayed on this website infringes upon your intellectual property rights, please contact the original content provider directly.
E. Fair Use Notice
Some content displayed on this website may fall under the "fair use" provisions of copyright law for purposes such as commentary, criticism, news reporting, research, or educational purposes. If you believe any content violates fair use guidelines, please reach out directly to the original source of the content for resolution.
Virus Scanning for Your Peace of Mind:
The files provided below have already been scanned for viruses by their original source. However, if you’d like to double-check before downloading, you can easily scan them yourself using the following steps:
How to scan a direct download link for viruses:
- 1- Copy the direct link to the file you want to download (don’t open it yet). (a free online tool) and paste the direct link into the provided field to start the scan.
- 2- Visit VirusTotal (a free online tool) and paste the direct link into the provided field to start the scan.
- 3- VirusTotal will scan the file using multiple antivirus vendors to detect any potential threats.
- 4- Once the scan confirms the file is safe, you can proceed to download it with confidence and enjoy your content.
Available Downloads
- Source: Internet Archive
- Internet Archive Link: Archive.org page
- All Files are Available: Yes
- Number of Files: 14
- Number of Available Files: 14
- Added Date: 2014-10-22 17:48:18
- Scanner: Internet Archive Python library 0.7.2
- PPI (Pixels Per Inch): 300
- OCR: ABBYY FineReader 9.0
Available Files:
1- Text PDF
- File origin: original
- File Format: Text PDF
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512.pdf
- Direct Link: Click here
2- Item Tile
- File origin: original
- File Format: Item Tile
- File Size: 0.00 Mbs
- File Name: __ia_thumb.jpg
- Direct Link: Click here
3- Metadata
- File origin: original
- File Format: Metadata
- File Size: 0.00 Mbs
- File Name: pubmed-PMC4020895_files.xml
- Direct Link: Click here
4- JSON
- File origin: original
- File Format: JSON
- File Size: 0.00 Mbs
- File Name: pubmed-PMC4020895_medline.json
- Direct Link: Click here
5- Metadata
- File origin: original
- File Format: Metadata
- File Size: 0.00 Mbs
- File Name: pubmed-PMC4020895_meta.sqlite
- Direct Link: Click here
6- Metadata
- File origin: original
- File Format: Metadata
- File Size: 0.00 Mbs
- File Name: pubmed-PMC4020895_meta.xml
- Direct Link: Click here
7- DjVu
- File origin: derivative
- File Format: DjVu
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512.djvu
- Direct Link: Click here
8- Animated GIF
- File origin: derivative
- File Format: Animated GIF
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512.gif
- Direct Link: Click here
9- Abbyy GZ
- File origin: derivative
- File Format: Abbyy GZ
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512_abbyy.gz
- Direct Link: Click here
10- DjVuTXT
- File origin: derivative
- File Format: DjVuTXT
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512_djvu.txt
- Direct Link: Click here
11- Djvu XML
- File origin: derivative
- File Format: Djvu XML
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512_djvu.xml
- Direct Link: Click here
12- Single Page Processed JP2 ZIP
- File origin: derivative
- File Format: Single Page Processed JP2 ZIP
- File Size: 0.01 Mbs
- File Name: PMC4020895-CPAA.S62512_jp2.zip
- Direct Link: Click here
13- Scandata
- File origin: derivative
- File Format: Scandata
- File Size: 0.00 Mbs
- File Name: PMC4020895-CPAA.S62512_scandata.xml
- Direct Link: Click here
14- Archive BitTorrent
- File origin: metadata
- File Format: Archive BitTorrent
- File Size: 0.00 Mbs
- File Name: pubmed-PMC4020895_archive.torrent
- Direct Link: Click here
Search for “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” downloads:
Visit our Downloads Search page to see if downloads are available.
Find “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” in Libraries Near You:
Read or borrow “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” from your local library.
Buy “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” online:
Shop for “Incidence And Management Of Adverse Events In Patients With Relapsed And/or Refractory Multiple Myeloma Receiving Single-agent Carfilzomib.” on popular online marketplaces.
- Ebay: New and used books.